DynapIP

Project "DynapIP" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Nowadays, ~220M of the worldwide population of which over 50M only in EU, currently live with more than one chronic condition. Early and accurate detection of adverse events are fundamental for proper clinical management. To meet this need, the healthcare system is becoming increasingly personalized with the help of self-health monitoring systems and in particular medical wearable devices. However, constant monitoring generates large amounts of raw data which must be stored and processed to extract pathological biomarkers. Normally, this is done using microprocessors commonly found in computers as central processing units (CPUs) or graphic processing units (GPUs), or on specialized microprocessors such as digital signal processors (DSPs) that have some limitations as implying high power consumption (>100W) and no real time signal processing. aiCTX offers DynapIP, a neuromorphic chip with extremely long battery life (3 months) and low-power consumption (<100uW) able to perform sophisticated signal processing and react to sensory input in real-time enabling continuous monitoring and real time analysis of biological signals captured by wearable medical devices. The hardware can be fully customized based on client needs and these approaches can be applied to a wide variety of biosensors, such as ECG, EOG, EMG and EEG. Wearable devices using DynapIP automatically identify in real-time (less than 100ms) pathological events with high accuracy facilitating faster and immediate diagnosis for healthcare personnel. During the feasibility assessment, a go-to-market strategy will be established, as well as further development plan will be drafted. During the innovation project, aiCTX will optimize the existing neuron/synapses hardware modules for different biosensors and the software integration to support the new hardware modules of the DynapIP. Pilot study for validation of biosignal analysis and functionality of the technology will be conducted together with secured partners